Every earnings call for AUROPHARMA — management tone, guidance, KPIs and promise tracking, quarter by quarter.
AUROPHARMA · 6 transcripts · Healthcare · latest Q4 FY26Revenue (Q4 FY26) ₹8,853 cr; EBITDA (Q4 FY26) ₹1,801 cr (+2% YoY); EBITDA Margin (Q4 FY26) 20.3%. FY26 Revenues of ₹33,653 crores, up 6% YoY (9.5% ex-gRevlimid).
Read full transcript & analysisConsolidated Revenue ₹8,646 cr (+8% YoY); EBITDA ₹1,773 cr (+9% YoY); EBITDA Margin 20.5%. Consolidated revenue grew by 8.4% YoY to ₹8,646 crores.
Read full transcript & analysisConsolidated Revenue ₹8,286 cr (+6% YoY); EBITDA ₹1,678 cr (+7% YoY); EBITDA Margin 20.3%. Consolidated revenues grew 6% YoY to ₹8,286 crores.
Read full transcript & analysisRevenue ₹7,868 cr (+4% YoY); EBITDA ₹1,603 cr; EBITDA Margin 20.4%. Consolidated revenues grew by 4% year-on-year to ₹7,868 crores.
Read full transcript & analysisRevenue (FY25) ₹31,724 cr (+9% YoY); EBITDA (FY25) ₹6,605 cr; EBITDA Margin (FY25) 20.8%. FY25 revenues stood at Rs. 31,724 crores and EBITDA at Rs. 6,605 crores, marking a comfortable margin of 20.8%.
Read full transcript & analysisRevenue ₹7,979 cr; EBITDA ₹1,628 cr; EBITDA Margin 20.4%. Highest ever quarterly revenues of ₹7,979 crores.
Read full transcript & analysis